Surf Air Mobility

RALLYBIO (NASDAQ: RLYB) STOCK QUOTE

Last Trade: US$1.34 0.04 3.08
Volume: 48,080
5-Day Change: -6.29%
YTD Change: -43.93%
Market Cap: US$55.540M

LATEST NEWS FROM RALLYBIO

NEW HAVEN, Conn. / Jul 09, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Jonathan Lieber, Chief Financial Officer of Rallybio, will present a corporate overview at the 2024 Jones Healthcare Seaside Summit on July 15, 2024 at 8:00 a.m. PT (11:00... Read More
First Reported Large-Scale Analysis of FNAIT Risk Across Broad Population of Diverse Ancestries Topline Results Suggest a Significant Increase in the Number of Pregnancies at Higher Risk for FNAIT Annually and the RLYB212 Addressable Market Rallybio On Track to Initiate RLYB212 Phase 2 Dose Confirmation Study in Pregnant Women at Higher Risk for FNAIT in 2H 2024 NEW HAVEN, Conn. / Jun 17, 2024 / Business Wire / Rallybio... Read More
On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 2H 2024 $94.2 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2024; Provides Runway into Mid-2026 NEW HAVEN, Conn. / May 09, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for... Read More
NEW HAVEN, Conn. / May 07, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Steve Uden, M.D., Chief Executive Officer of Rallybio, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday,... Read More
Data Support HPA-1a Negative Frequency of More than 2% in Nearly 200,000 Screened Pregnant Women Among HPA-1a Negative Pregnant Women, Approximately 33% are at Higher Risk for Alloimmunization NEW HAVEN, Conn. / Apr 17, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with... Read More
Rallybio to Receive Funding for FNAIT Awareness Initiative and Equity Investment from Johnson & Johnson NEW HAVEN, Conn. / Apr 10, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced a collaboration with Johnson & Johnson 1 to... Read More
NEW HAVEN, Conn. / Apr 01, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that data from a systematic literature review assessing the frequency of fetal and neonatal alloimmune thrombocytopenia (FNAIT) risk among pregnant... Read More
Received Protocol Assistance Feedback from European Medicines Agency on the Phase 2 Study for RLYB212; Company to Proceed Forward with Clinical Trial Application Process in Europe Phase 2 Dose Confirmation Study for RLYB212 in Pregnant Women at Higher Risk for FNAIT Expected to Initiate in 2H 2024 $109.9 million Cash, Cash Equivalents and Marketable Securities as of December 31, 2023; Provides Runway into Mid-2026 NEW HAVEN,... Read More
NEW HAVEN, Conn. / Feb 26, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Steve Uden, M.D., Chief Executive Officer of Rallybio, will participate in a panel discussion, “Orphan Bone & Neuromuscular Diseases,” at the TD... Read More
Prioritization of Phase 2-ready clinical-stage programs: RLYB212 for the prevention of FNAIT and RLYB116, a C5 inhibitor for the treatment of patients with complement-mediated diseases Anticipated cost savings, including a 45% workforce reduction, extends cash runway into mid-2026 NEW HAVEN, Conn. / Feb 06, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB) today announced the prioritization of its portfolio and a... Read More
Phase 2 Study for RLYB212 Expected to Initiate in 2H 2024 Company to Provide Update on Phase 2 Discussions with European Medicines Agency for RLYB212 in 1H 2024 Cash Runway Extended into 3Q 2025 NEW HAVEN, Conn. / Jan 04, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with... Read More
100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing Data Supports the Study of RLYB116 as a Differentiated Therapeutic for the Treatment of Generalized Myasthenia Gravis Company Announces Extension of Runway to 3Q 2025 As Part of Portfolio Prioritization Conference Call and Webcast Today at 8:30 AM Eastern Time NEW HAVEN, Conn. / Dec 20, 2023 / Business... Read More
FNAIT Natural History Study to Inform Frequency of FNAIT Risk in a Broad and Diverse Population of Pregnant Women -- Study Designed to Provide a Contemporary Control Dataset to Support a Future Registrational Trial in Pregnant Women -- NEW HAVEN, Conn. / Dec 09, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of... Read More
Preliminary Data Support RLYB212 Once Monthly Subcutaneous Dosing in Phase 2 Study RLYB212 Toxicology Package Complete, Including Maternal-Fetal Toxicology; Key Activity to Support Phase 2 and Phase 3 Studies in Pregnant Women RLYB212 Phase 2 Study Expected To Commence in 2H 2024 NEW HAVEN, Conn. / Nov 28, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB) today announced preliminary data from the completed multiple... Read More
RLYB212 Phase 1 Multiple Dose Cohort Complete and on Track for 4Q 2023 Data Release Initial Data from RLYB116 Phase 1 Multiple Ascending Dose Study Including Safety, PK and PD on Track for 4Q 2023 Release $121.4 million cash, cash equivalents and marketable securities as of September 30, 2023; Provides Runway into 1Q 2025 NEW HAVEN, Conn. / Nov 09, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB) today reported... Read More
NEW HAVEN, Conn. / Nov 08, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences: Stifel 2023 Healthcare Conference in New York, NY on Wednesday, November 15, 2023.... Read More
NEW HAVEN, Conn. / Nov 02, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract for the Rallybio Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) natural history study has been accepted for poster presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting, which will be held December 9-12, 2023, in San Diego, California. Details of the poster... Read More
NEW HAVEN, Conn. / Oct 03, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will participate in a panel discussion, “Novel Platform Technologies in Rare Disease and... Read More
First-In-Human Single Ascending Dose Clinical Data for RLYB116 Demonstrated a Reduction in Free C5 Greater than 99% at 24 Hours for the 100 mg dose and at 12, 24, and 72 Hours for the 300 mg dose in Healthy Participants Mean Estimated Elimination Half-Life for RLYB116 was > 300 Hours No Severe or Serious Adverse Events with Single-Dose Administration of RLYB116 Phase 1 Multiple Ascending Dose Study of RLYB116 Ongoing;... Read More
NEW HAVEN, Conn. / Aug 31, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences: 2023 Wells Fargo Healthcare Conference in Everett, MA on Thursday, September 7, 2023.... Read More
RLYB212 Phase 1b Proof-of-Concept Study Results Presented at the 31 st Congress of the International Society of Thrombosis and Haemostasis (ISTH) in June 2023 RLYB212 Phase 1 Multiple Dose Cohort Study Results Expected in 4Q 2023 Initial Data from RLYB116 Phase 1 Multiple Ascending Dose Study Including Safety, PK and PD Expected in 4Q 2023 $137.8 million cash, cash equivalents and marketable securities as of June 30, 2023;... Read More
NEW HAVEN, Conn. / Aug 02, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Steve Uden, M.D., Chief Executive Officer of Rallybio, will participate in a panel discussion, “When You’re One in a Million – Orphan Drug... Read More
NEW HAVEN, Conn. / Jul 11, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract reporting results from the Phase 1 first-in-human single ascending dose clinical study of RLYB116 has been accepted for presentation as a poster at the 29 th International Complement Workshop (ICW), which will take place in Newcastle, UK from August 31 - September 5. RLYB116 is a novel, potentially... Read More
Martin Mackay, Ph.D., CEO, Chairman of the Board and Co-Founder of Rallybio To Become Executive Chairman NEW HAVEN, Conn. / Jun 29, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Stephen Uden, M.D., Rallybio’s President,... Read More
RLYB212 Demonstrated Dose-Dependent, Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects Mean Reduction in Platelet Elimination Half-Life After Subcutaneous Administration of RLYB212 was ≥90% in both RLYB212 Dose Groups, Achieving Proof-of-Concept Criteria Phase 2 Study in Pregnant Women at Higher Risk of HPA-1a Alloimmunization to be Initiated in 2H 2024 Phase 1 Multiple Dose... Read More
Data from the RLYB212 Phase 1b Proof-of-Concept Study to be Featured as an Oral Presentation at ISTH Company to Host Webcast Following ISTH Oral Presentation of RLYB212 NEW HAVEN, Conn. / Jun 09, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,... Read More
NEW HAVEN, Conn. / Jun 01, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Company management will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 9 at 9:00AM ET in New York, NY. A live... Read More
RLYB212 Phase 1b Proof-of-Concept Study Results to be Presented at 31 st Congress of the International Society of Thrombosis and Haemostasis (ISTH) in June 2023 Phase 1 Multiple Dose Cohort RLYB212 Study Initiated in 1Q 2023; Data Expected in 4Q 2023 Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 $150.4 million cash, cash equivalents and marketable... Read More
NEW HAVEN, Conn. / May 08, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a fireside chat at the JMP Securities 2023 Life Sciences Conference on Monday, May 15 at 2:30 p.m. ET in New... Read More
Data Support Potential Use of an Anti-HPA-1a Antibody as Prophylaxis for FNAIT In March 2023, Rallybio Announced Clinical Proof-of-Concept Achieved for its Lead Product Candidate, RLYB212, a Monoclonal Anti-HPA-1a Antibody, in the First Quarter of 2023 NEW HAVEN, Conn. / Apr 06, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB) today announced publication of Phase 1 / 2 proof-of-concept results for RLYB211, a... Read More
NEW HAVEN, Conn. / Apr 03, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract for RLYB212 reporting results from the Phase 1b proof-of-concept study has been accepted for presentation at the 31 st Congress of the International Society on Thrombosis and Haemostasis (ISTH), which will take place in Montreal from June 24-28. RLYB212 is an anti-HPA-1a monoclonal antibody being developed... Read More
Proof-of-Concept Achieved for RLYB212; Showed Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects Phase 1 Multiple Dose Cohort RLYB212 Study Initiated Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 $169.0 million cash, cash equivalents and marketable securities as of December 31, 2022; Provides Runway into 1Q... Read More
RLYB212 Showed Rapid Elimination of Transfused, HPA-1a Positive Platelets in HPA-1a Negative Subjects Clinical Findings and Safety Profile Consistent with Previously Reported Data; Continue to Support the Potential for RLYB212 as a Prophylactic Treatment for FNAIT Company Expects to Present Results at a Scientific Conference in 2023 Rallybio Corporation (Nasdaq: RLYB) today announced that clinical proof-of-concept has been... Read More
EyePoint Pharmaceuticals, Inc., a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, and Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced a research collaboration. The... Read More
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jonathan I. Lieber will join as the Company’s Chief Financial Officer (CFO), effective February 1, 2023. Mr. Lieber succeeds Jeffrey Fryer, CPA, Rallybio’s Co-Founder and CFO. The company announced... Read More
Phase 1b Proof-of-Concept Data for RLYB212 on track for 1Q 2023 Initiated Phase 1 Multiple Ascending Dose Study of RLYB116 in 4Q 2022; Safety, PK and PD Data Expected in 2H 2023 Cash Runway Extended into 1Q 2025 following November 2022 Follow-On Offering Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for... Read More
Data Demonstrates that HPA-1a Alloimmunization can be Prevented with Prophylactic Administration of Low Levels of HPA-1a-specific Antibodies Rallybio Corporation (Nasdaq: RLYB) today announced publication of preclinical study results for two human HPA-1a-specific antibodies in development for the prevention of FNAIT. The results demonstrate that low doses of the two HPA-1a-specific antibodies, the polyclonal candidate... Read More
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 7, 2022, at 1:40 p.m. ET. A live webcast of the fireside... Read More
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences: Jefferies London Healthcare Conference in London, United Kingdom on Tuesday, November 15, 2022, at 8:35 a.m. GMT (3:35 a.m. EST) Evercore... Read More
Rallybio Corporation (“Rallybio”) (Nasdaq: RLYB) today announced the pricing of an underwritten public offering of 5,000,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 3,333,388 shares of its common stock at a price of $5.9999 per pre-funded warrant, which represents the per share public... Read More
Rallybio Corporation (“Rallybio”) (Nasdaq: RLYB) today announced the commencement of a proposed public offering of $75 million of its shares of common stock (and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock). All of the shares and pre-funded warrants will be offered by Rallybio. Rallybio also expects to grant the underwriters a 30-day option to purchase additional... Read More
Preliminary results from Phase 1b study of RLYB212 showed rapid and complete elimination of transfused platelets in all subjects to date; Proof-of-concept data expected in 1Q 2023 Positive 100 mg results of Phase 1 study of RLYB116 showed reduction of >99% in free C5 with the potential for weekly or less frequent dosing Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and... Read More
100 mg Results Demonstrated a Reduction of >99% in Free C5 with the Potential for Weekly or Less Frequent Self-Administered Dosing RLYB116 Administered as a Single 100 mg dose was Generally Well-Tolerated Phase 1 Multiple Ascending Dose Study Expected to Commence in 1Q 2023 Rallybio Corporation (Nasdaq: RLYB) today announced positive topline results from its Phase 1 single ascending dose (SAD) study in healthy participants... Read More
Rallybio Corporation (Nasdaq: RLYB) today announced positive preliminary results from its ongoing Phase 1b proof-of-concept study of RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). These data demonstrate that one week after a single subcutaneous dose, RLYB212 was able to eliminate transfused HPA-1a positive platelets rapidly compared to placebo in a... Read More
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent program and corporate developments. “We continue to progress our pipeline toward planned upcoming milestones.... Read More
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that it has appointed Wendy K. Chung, M.D., Ph.D., to its Board of Directors. “Wendy is a tremendous addition to our Board of Directors. Her extensive clinical experience and deep scientific expertise... Read More
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jeffrey Fryer, CPA, will retire from his position as Chief Financial Officer (CFO). Mr. Fryer will continue to serve as Rallybio’s CFO until a new CFO has been appointed and will retire from the... Read More
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences: Jefferies Healthcare Conference in New York, NY on Wednesday, June 8, 2022 at 10:30 a.m. ET. JMP Securities Life Sciences Conference in... Read More
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the first quarter ended March 31, 2022 and provided an update on recent program and corporate developments. “We continue to move forward with our mission of discovering, developing,... Read More
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that it has obtained worldwide exclusive rights to Sanofi’s KY1066, which will be referred to as RLYB331 going forward, a preclinical potentially first-in-class antibody. RLYB331 has the potential to... Read More
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that it has appointed Christine Nash, MBA and Hui Liu, Ph.D., to its Board of Directors. In addition, Tim Shannon, M.D. notified the company that he will resign from the Board, effective at Rallybio’s... Read More
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on recent corporate developments. “Following our successful initial public offering in August 2021, we... Read More
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Martin Mackay, Ph.D., Chief Executive Officer of Rallybio, will participate in a panel discussion, “ Neuromuscular” at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 9:10... Read More
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Ami Bavishi has joined as the company’s Head of Investor Relations and Corporate Communications. Ms. Bavishi brings more than 10 years of experience to Rallybio and will be responsible for... Read More
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today provided an update on recent accomplishments and announced expected upcoming milestones. The Company will present these updates at the 40 th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022... Read More
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced data from its ongoing Phase 1/2 study of RLYB211 showing significant benefit over placebo. RLYB211, a plasma-derived polyclonal anti-HPA-1a antibody, is being evaluated for the prevention of Fetal and... Read More
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021 at 8:00 a.m. ET. Rallybio will also host one-on-one... Read More
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a pre-recorded fireside chat at the Jefferies London Healthcare Conference. Rallybio will also host one-on-one meetings on Thursday, November 18, 2021. The... Read More
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the third quarter ended September 30, 2021 and provided an update on recent corporate developments. “We continue to work with unwavering commitment to deliver transformative impact... Read More
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported its financial results for the second quarter ended June 30, 2021 and provided an update on recent corporate developments. “Since our founding in 2018, Rallybio has made consistent progress towards... Read More
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced the closing of its initial public offering of 7,130,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 930,000 additional shares of common... Read More

COPYRIGHT ©2022 GREEN STOCK NEWS